Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:53 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide
NCT03362515 · Thomas Jefferson University · PHASE2 · terminated · last registry update 2023-08-30 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated prematurely due to low enrollment numbers and the development of better drugs to treat polyps (ie. Biologics) which were not available when the study began.” | – | Registry record, Thomas Jefferson University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC12A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-08-20Results posted on the registry: Indiana University, Nitrates + Loop Diuretics (NCT03259165)
- 2024-08-20Also stopped (terminated): Indiana University, Nitrates + Loop Diuretics (NCT03259165)
- 2024-08-02Results posted on the registry: Shionogi, MT-1186 + Rosuvastatin (NCT04481789)
- 2024-08-02Phase 3 first posted: Helwan University, Acetazolamide + Dapagliflozin 10mg (NCT06535529)
- 2024-07-25Also stopped (terminated): Institut de Recherches Internationales Servier, Bumetanide Oral Solution + Placebo (NCT03715166)
- 2024-05-14Phase 3 first posted: Ospedale San Raffaele, Torasemide + Spironolactone (NCT06413082)
- 2024-05-09Phase 3 first posted: European Organisation for Research and Treatment of Cancer - EORTC, Duloxetine 60 MG + Furosemide 40 mg (NCT06407401)
- 2024-04-18Results posted on the registry: Melanie Maykin, MD, Furosemide (NCT04615624)
- 2024-03-25Results posted on the registry: Hamilton Health Sciences Corporation, Intravenous albumin + Normal saline (NCT02055872)
- 2024-03-15Results posted on the registry: Vanderbilt University Medical Center, Dapagliflozin 10 MG (NCT04298229)
- 2024-02-09Phase 3 first posted: University Hospital Hradec Kralove, Furosemide 40 mg + Levodropropizine (NCT06252454)
- 2024-01-11Results posted on the registry: University of New Mexico, Bumetanide (NCT02593526)
- 2024-01-11Also stopped (terminated): University of New Mexico, Bumetanide (NCT02593526)
- 2024-01-05Results posted on the registry: National Cardiovascular Center Harapan Kita Hospital Indonesia, Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL) + NaCl 0.9% (NCT04919564)
- 2023-12-11Also stopped (terminated): Dr. John Muscedere, Nebulized Furosemide + Nebulized Saline (NCT04588792)
- 2023-11-02Results posted on the registry: PT. Kimia Farma (Persero) Tbk, Furosemide 40 mg + Lasix® 40 mg Tablet (NCT04982874)
- 2023-10-23Results posted on the registry: Wright State University, furosemide + labetalol (NCT04343235)
- 2023-10-23Also stopped (terminated): Wright State University, furosemide + labetalol (NCT04343235)
- 2023-09-14Results posted on the registry: Maruho Co., Ltd., CLS006 + CLS006 Vehicle (NCT03259620)
- 2023-09-14Results posted on the registry: Maruho Co., Ltd., CLS006 (Furosemide) Topical Gel + Vehicle Topical Gel (NCT02971891)
- 2023-08-29Also stopped (terminated): Nuwellis, Inc., IV Loop Diuretics (LD) (NCT01474200)
- 2023-08-01Results posted on the registry: scPharmaceuticals, Inc., Furoscix Infusor (NCT04593823)
- 2023-07-27Phase 3 first posted: Wroclaw Medical University, Furosemide intravenous infusion + Continous intravenous infusion of 0.9% Sodium Chloride solution (NCT05962255)
- 2023-07-17Results posted on the registry: Boehringer Ingelheim, BI 730357 + CRESTOR® (NCT04590937)
- 2023-07-11Phase 3 first posted: Tehran University of Medical Sciences, a drug against SLC12A1 (NCT05940220)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision